Clinical Trial Update: Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Follow-up protocol for the Phase I/II study of OPN-305 in second- or third-line lower-risk myelodysplastic syndrome; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• OPN-305 (OPN-305)

Snippet

Sponsor: Opsona Therapeutics Ltd. | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED